Healthcare provider profile · identity verified

Brian Crotty, D.O.

Family Practice · TULSA, OK · NPI 1003885583

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	324	105
Lisinopril	Lisinopril	321	98
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	244	52
Atorvastatin Calcium	Atorvastatin Calcium	242	80
Levothyroxine Sodium	Levothyroxine Sodium	180	60
Omeprazole	Omeprazole	151	53
Gabapentin	Gabapentin	145	41
Metoprolol Succinate	Metoprolol Succinate	134	44
Zolpidem Tartrate	Zolpidem Tartrate	123	22
Hydrochlorothiazide	Hydrochlorothiazide	120	39
Furosemide	Furosemide	118	38
Albuterol Sulfate Hfa	Albuterol Sulfate	117	39
Losartan Potassium	Losartan Potassium	103	36
Diclofenac Sodium	Diclofenac Sodium	94	23
Metformin Hcl	Metformin Hcl	93	38
Pregabalin	Pregabalin	93	22
Pravastatin Sodium	Pravastatin Sodium	90	27
Simvastatin	Simvastatin	89	28
Tamsulosin Hcl	Tamsulosin Hcl	88	32
Citalopram Hbr	Citalopram Hydrobromide	83	27
Doxazosin Mesylate	Doxazosin Mesylate	83	22
Potassium Chloride	Potassium Chloride	83	22
Tramadol Hcl	Tramadol Hcl	82	21
Metoprolol Tartrate	Metoprolol Tartrate	81	28
Alendronate Sodium	Alendronate Sodium	73	19
Rosuvastatin Calcium	Rosuvastatin Calcium	72	22
Carvedilol	Carvedilol	70	25
Alprazolam	Alprazolam	67	14
Clopidogrel	Clopidogrel Bisulfate	66	21
Atenolol	Atenolol	62	19
Baclofen	Baclofen	62	21
Trazodone Hcl	Trazodone Hcl	58	24
Glipizide	Glipizide	56	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	55	17
Meloxicam	Meloxicam	55	20
Warfarin Sodium	Warfarin Sodium	55	13
Pioglitazone Hcl	Pioglitazone Hcl	51	16
Metformin Hcl Er	Metformin Hcl	50	17
Montelukast Sodium	Montelukast Sodium	50	16
Eliquis	Apixaban	49	18
Fluoxetine Hcl	Fluoxetine Hcl	49	15
Pantoprazole Sodium	Pantoprazole Sodium	49	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	47	17
Sertraline Hcl	Sertraline Hcl	47	18
Famotidine	Famotidine	46	20
Terazosin Hcl	Terazosin Hcl	46	suppressed
Duloxetine Hcl	Duloxetine Hcl	45	17
Lovastatin	Lovastatin	43	12
Allopurinol	Allopurinol	41	15
Donepezil Hcl	Donepezil Hcl	41	16
Diazepam	Diazepam	38	11
Venlafaxine Hcl Er	Venlafaxine Hcl	37	12
Valsartan	Valsartan	34	11
Celecoxib	Celecoxib	32	14
Lorazepam	Lorazepam	32	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	12
Hydroxyzine Hcl	Hydroxyzine Hcl	29	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	29	suppressed
Ozempic	Semaglutide	29	suppressed
Azithromycin	Azithromycin	28	27
Carisoprodol	Carisoprodol	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Methylprednisolone	Methylprednisolone	27	22
Propranolol Hcl Er	Propranolol Hcl	27	suppressed
Spironolactone	Spironolactone	26	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	19
Clonidine Hcl	Clonidine Hcl	23	suppressed
Memantine Hcl	Memantine Hcl	22	suppressed
Mounjaro	Tirzepatide	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Finasteride	Finasteride	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	12
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Glimepiride	Glimepiride	18	suppressed
Jardiance	Empagliflozin	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Estradiol	Estradiol	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Glipizide Er	Glipizide	15	suppressed
Ibandronate Sodium	Ibandronate Sodium	15	suppressed
Linzess	Linaclotide	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Cephalexin	Cephalexin	14	11
Ezetimibe	Ezetimibe	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Digoxin	Digoxin	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Levetiracetam Er	Levetiracetam	11	suppressed
Trulicity	Dulaglutide	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error